Organon & Co. OGN · NYSE
$13.77 +0.18% (+$0.03)
Summary
51 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
What to watch
- Earnings per share fell by 41% a year over the last 3 years.
- Repaying its net debt would take 5.7 years of operating profit.
- It cut its dividend by 70% last year.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.3 USD for 1 USD of yearly profit. Over the last five years it was 6.3 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 1.0% a year over 5 years. Over the last 3 years it grew by 0.2% a year. Earnings per share fell by 41% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 47 USD
- Research and development 5.8 USD
- Sales and administration 28 USD
- Taxes and other 16 USD
- Net profit 3.4 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 3.4 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 17.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.58%
- Paid out of profit
- 10%
You receive $0.08 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 4
- Sell 3
Today's price within the analysts' price targets
The average target of $13 is 5.6% below today's price. 22% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- Non-US 43%
- Europe And Canada 15%
- UNITED STATES 15%
- Latin America, Middle East, Russia And Africa 9.9%
- Asia Pacific and Japan 9.2%
- Other 8.5%
Non-US brings in 43% of revenue. UNITED STATES grew fastest, by 4.2% a year.
Segments in detail